4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BeOne Medicines AG (6160) operates in the Biotechnology industry and is headquartered in Basel, Switzerland with about 12,000 employees. Its market capitalization is roughly $309 billion. In the fiscal year ended 2025-12-31, 6160 reported $5.3B in revenue and $287M in net income.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $5.3B | $3.8B | $2.5B | $1.4B | — |
| Gross Profit | $4.7B | $3.2B | $2.1B | $1.1B | — |
| Operating Income (EBIT) | $447M | ($568M) | ($1.2B) | ($1.8B) | — |
| Net Income | $287M | ($645M) | ($882M) | ($2.0B) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.7B | $1.5B | $1.5B | $1.4B | $1.3B | — |
| Gross Profit | $1.5B | $1.3B | $1.4B | $1.2B | $1.2B | — |
| Operating Income (EBIT) | $325M | $250M | $185M | $163M | $88M | — |
| Net Income | $237M | $227M | $66M | $125M | $94M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $8.2B | $5.9B | $5.8B | $6.4B | — |
| Total Liabilities | $3.8B | $2.6B | $2.3B | $2.0B | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6160 viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms